Why SAP S/4HANA Migration in Pharma Must Be Designed Around Compliance

Table of contents

• S/4HANA Migration in Pharma Is More Than an IT Project
• Start With the Process, Not the SAP Module
• Build Compliance Into Solution Design
• Define Validation Scope Early
• Treat Data Migration as a Data Integrity Exercise
• Design Traceability From the Start
• Test What Can Go Wrong
• Remember: The Process May Extend Beyond SAP
• Use Migration to Reduce Unnecessary Complexity
• User Adoption Is Part of the Control Environment
• Go-Live Is Not the End
• Pharma S/4HANA Migration Readiness Checklist
• A Regulated S/4HANA Migration Lifecycle
• Compliance Is a Design Decision
• Is Your Pharma S/4HANA Program Ready?

In pharma, a process is not complete when it works. It must also be controlled, traceable and defensible.

That changes how an SAP S/4HANA migration should be approached.

Moving from SAP ECC to S/4HANA already involves major decisions around processes, data, integrations, infrastructure, testing and user adoption. In a pharmaceutical environment, those decisions may also affect regulated activities, critical data and the evidence an organization relies on to demonstrate control.

Compliance therefore cannot be a checkpoint added shortly before go-live.

It has to be part of the migration design from the beginning.

S/4HANA Migration in Pharma Is More Than an IT Project

An S/4HANA migration can reshape the way an organization operates.

Processes may be standardized. Customizations may be retired. Master data can be restructured. Roles and authorizations may change. Interfaces are rebuilt, historical information is migrated or retained, and users adopt new ways of working.

In pharmaceutical operations, some of those changes can affect GxP-relevant processes and records.

EU GMP Annex 11 establishes an important principle for computerized systems: applications should be validated and IT infrastructure qualified. It also states that replacing a manual operation with a computerized system should not reduce product quality, process control or quality assurance, or increase overall process risk.

For an S/4HANA program, the practical implication is clear:

Regulated processes, critical data and required controls need to be understood before the future solution is fully designed.

Otherwise, teams risk trying to validate decisions after they have already been made.

Start With the Process, Not the SAP Module

Not every SAP function carries the same regulatory significance.

Instead of asking only:

“Which modules are we migrating?”

Pharmaceutical organizations should ask:

“Which regulated business processes depend on these capabilities, data and integrations?”

This distinction is important because validation should follow risk.

Annex 11 calls for risk management throughout the computerized-system lifecycle and for the extent of validation and data-integrity controls to be based on a justified and documented risk assessment.

The objective is not to produce the maximum amount of validation documentation.

It is to establish the right controls and evidence for the risks that matter.

Build Compliance Into Solution Design

Requirements, test scripts, approvals and validation reports are important, but documentation cannot compensate for weak process design.

A workflow may technically perform the expected transaction while still creating risk if responsibilities are unclear. An interface may transfer data successfully but lack appropriate exception handling. A migration may move every required record while leaving ownership of critical data unresolved.

That is why compliance questions belong in design workshops:

• Who can create, change and approve critical information?
• Which data is critical, and who owns it?
• Where is segregation of duties required?
• Which actions need to be traceable?
• What happens when an integration fails?
• How are exceptions detected and resolved?
• What evidence will demonstrate that the process worked as intended?

Quality, business and technology teams need to answer these questions together while there is still time for the answers to shape the solution.

Define Validation Scope Early

Unclear validation scope creates unnecessary complexity.

If teams cannot identify which processes, data, interfaces and controls are relevant to regulated activities, they may either validate too much or discover important gaps too late.

A stronger approach is to establish the validation boundary early and refine it as the solution develops.

That means aligning on the system’s intended use, GxP-relevant processes, critical data, key integrations, controls and responsibilities.

This gives the program a rational basis for deciding what needs deeper testing, what evidence is required and where validation effort should be concentrated.

Treat Data Migration as a Data Integrity Exercise

Data migration is often described technically:

Extract → Cleanse → Map → Transform → Load → Reconcile

In pharma, one more concept needs to sit across the entire sequence:

Ownership.

Who decides what should migrate? Who approves transformation rules? Who handles exceptions? Who confirms that the migrated information remains complete, accurate and suitable for its intended use?

FDA guidance on data integrity emphasizes that CGMP data should be reliable and accurate and encourages meaningful, risk-based strategies for managing data-integrity risks.

For an S/4HANA migration, this means establishing clear ownership of critical master and transactional data before migration cycles begin.

Technical completeness alone is not enough.

The organization also needs confidence that the resulting data remains trustworthy and usable within the process that depends on it.

Design Traceability From the Start

S/4HANA transformation can change approval responsibilities, workflows, integrations, authorizations and the way information moves between systems.

Traceability therefore needs to be considered during architecture and process design—not reconstructed before go-live.

A useful relationship is:

Business Requirement → Risk → Control → System Function → Test → Evidence

When that chain exists from the beginning, validation becomes a structured demonstration that the solution performs as intended.

When it has to be reconstructed later, teams spend valuable time trying to establish why earlier decisions were made.

Test What Can Go Wrong

Testing should not focus only on the happy path.

Real operations involve incorrect data, rejected approvals, failed interfaces, unavailable systems and unauthorized actions.

For critical processes, teams should also ask:

What happens when the expected process fails?

Can the system detect the problem? Is the transaction controlled? Can users recover appropriately? Is the event traceable?

The goal is not the largest possible test library.

It is meaningful test coverage based on business and compliance risk.

Remember: The Process May Extend Beyond SAP

S/4HANA rarely operates alone.

Pharmaceutical ERP environments may connect with manufacturing systems, quality applications, warehouse platforms, serialization and track-and-trace solutions, analytics environments and external services.

A transaction can therefore work correctly inside S/4HANA while the overall process fails because information is incorrectly transformed, delayed or lost elsewhere.

For relevant integrations, teams need to understand:

• what information enters and leaves SAP;
• who owns it;
• how errors are identified;
• how failed transactions are handled;
• and how reconciliation is performed.

The technical system boundary may end at SAP. The regulated business process often does not.

Use Migration to Reduce Unnecessary Complexity

S/4HANA migration is also an opportunity to question years of accumulated ERP customization.

Some custom developments remain essential. Others reflect historical requirements that may no longer exist or may now be covered by standard S/4HANA capabilities.

Rather than automatically rebuilding everything, teams should ask:

Why does this customization exist? Is the requirement still valid? Can standard functionality meet it today?

Reducing unnecessary customization can simplify the future environment, including testing, support and change management.

A Practical Example From ITP

This principle can be seen in ITP’s work with pharmaceutical company Adalvo.

The project involved migration from SAP ECC to SAP S/4HANA with Microsoft Azure infrastructure, covering core SAP processes alongside Advanced Track and Trace for Pharmaceuticals.

The project used a blue-field migration approach and fit/gap analysis to determine where standard S/4HANA functionality could replace existing customization rather than simply reproducing the previous environment.

Read the Adalvo SAP S/4HANA case study

The lesson is not that every pharma organization should follow the same architecture.

It is that migration creates an opportunity to reassess processes, data and customization while maintaining the controls a regulated environment requires.

User Adoption Is Part of the Control Environment

A correctly configured system can still produce poor outcomes if people do not understand how to operate it.

New workflows may change responsibilities, approvals and familiar routines.

Training therefore needs to go beyond showing users where to click.

People should understand their responsibilities, the controls built into the process, why those controls matter and what to do when an exception occurs.

Change management is therefore not separate from a controlled transformation. It is part of making that transformation work in practice.

Go-Live Is Not the End

A controlled environment at go-live does not automatically remain controlled.

Roles change. Configuration evolves. New integrations are introduced. SAP updates occur. Business requirements develop.

Annex 11 addresses periodic evaluation of computerized systems to confirm that they remain in a valid state and compliant with GMP.

That means the migration needs to leave behind an operating model capable of maintaining control through appropriate change management, access governance, incident handling, documentation and periodic review.

Go-live is a milestone. Maintaining the validated state is a lifecycle responsibility.

Pharma S/4HANA Migration Readiness Checklist

Before detailed implementation accelerates, leadership should be able to answer these questions:

Regulatory scope: Have we identified the processes and system functions that support regulated activities?

Validation: Is validation scope defined and based on documented risk?

Data: Do critical data domains have clear owners and agreed migration and reconciliation rules?

Controls: Are responsibilities, approvals and authorizations reflected in the future process?

Traceability: Can critical requirements be connected to risks, controls, tests and evidence?

Integrations: Have interfaces supporting regulated processes been assessed end to end?

Testing: Does testing cover meaningful exceptions as well as successful transactions?

Adoption: Are users being prepared for their process responsibilities, not just the new interface?

Post-go-live: Is there a clear approach to change control, access governance and periodic review?

If several answers remain unclear, that is more than a validation concern.

It is a migration-readiness signal.

A Regulated S/4HANA Migration Lifecycle

Across every stage: Quality · Compliance · Data Integrity

Compliance Is a Design Decision

SAP S/4HANA gives pharmaceutical companies an opportunity to simplify processes, reduce unnecessary customization, strengthen data governance and create a more scalable digital core.

But modernization and compliance cannot be treated as separate objectives.

Strong migration programs bring IT, Quality, Compliance, Operations and business process owners together early enough to influence the future environment.

They define regulated scope early. They establish data ownership before migration. They build controls into processes. They test according to risk. And they plan for maintaining control after go-live.

Because the most important question is not simply:

Does the new system work?

It is:

Can we demonstrate that it works as intended, remains controlled and supports reliable, traceable processes throughout its lifecycle?

That is why compliance should not be added at the end of an SAP S/4HANA migration.

It should be designed into the transformation from the start.

Is Your Pharma S/4HANA Program Ready?

Before key configuration and migration decisions become difficult to reverse, assess whether your process scope, validation strategy, data ownership, testing approach and organizational readiness are aligned.

Our team specializes in delivering digital transformation consulting services for complex IT projects, helping organizations modernize processes, strengthen technology foundations, and build scalable transformation strategies. As one of the experienced digital transformation consulting companies, ITP combines SAP, cloud, AI, and enterprise transformation expertise to deliver solutions aligned with each client’s operational, regulatory, and long-term business needs.

Request a pharma S/4HANA and validation readiness workshop with ITP.